Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
J Magn Reson Imaging. 2022 Sep;56(3):725-736. doi: 10.1002/jmri.28059. Epub 2022 Jan 10.
Gadoxetic acid-enhanced magnetic resonance imaging (MRI) is useful in detecting liver metastases from pancreatic ductal adenocarcinoma (PDAC). However, the long examination time limits its utility in the initial workup of patients with PDAC.
To evaluate the incremental value of an abbreviated gadoxetic acid-enhanced MRI for the detection of liver metastases in patients with PDAC.
Retrospective.
Patients (N = 130) with potentially resectable PDAC (women, 58 [44.6%]).
FIELD STRENGTH/SEQUENCE: 1.5 T and 3 T; gradient dual-echo T1-weighted (in-phase and opposed-phase), fat-suppressed fast spin-echo T2-weighted, single-shot echo-planar diffusion-weighted, and three-dimensional fat-suppressed T1-weighted gradient-echo dynamic contrast-enhanced and hepatobiliary phase sequences, as well as contrast-enhanced computed tomography (CECT).
Three radiologists independently reviewed three different image sets to detect liver metastases: set 1, CECT alone; set 2, CECT and abbreviated MRI comprising fat-suppressed T2-weighted, diffusion-weighted, and hepatobiliary phase images; and set 3, CECT and standard gadoxetic acid-enhanced MRI.
Figure of merit (FOM) was compared using the jackknife alternative free-response receiver operating characteristics, and other per-lesion and per-patient diagnostic parameters for each image set were compared using McNemar's and Fisher's test. P < 0.05 was considered statistically significant.
A total of 43 liver metastases were identified in 13 patients. Reader-averaged FOM to detect liver metastases were significantly higher for sets 2 (0.884) and 3 (0.886) than for set 1 (0.609), while they were comparable between sets 2 and 3 (P = 0.96). The mean per-patient sensitivities, negative predictive values, and accuracies were significantly higher for sets 2 and 3 than for set 1, while those between sets 2 and 3 were not significantly different (not applicable, P > 0.99, and P > 0.99, respectively).
Gadoxetic acid-enhanced MRI combined with CECT had higher diagnostic performance than CECT alone for the detection of liver metastases in patients with PDAC. The incremental values were comparable for the abbreviated MRI and standard MRI.
3 TECHNICAL EFFICACY: Stage 2.
钆塞酸增强磁共振成像(MRI)在检测胰腺导管腺癌(PDAC)肝转移方面很有用。然而,较长的检查时间限制了其在 PDAC 患者初始检查中的应用。
评估缩短的钆塞酸增强 MRI 在检测 PDAC 患者肝转移中的附加价值。
回顾性。
(n=130)患有潜在可切除 PDAC 的患者(女性,58 [44.6%])。
场强/序列:1.5T 和 3T;梯度双回波 T1 加权(同相位和反相位)、脂肪抑制快速自旋回波 T2 加权、单次激发回波平面扩散加权、三维脂肪抑制 T1 加权梯度回波动态对比增强和肝胆期序列,以及对比增强 CT(CECT)。
三位放射科医生独立审查了三个不同的图像集以检测肝转移:集 1,仅 CECT;集 2,CECT 和缩短的 MRI 包括脂肪抑制 T2 加权、扩散加权和肝胆期图像;集 3,CECT 和标准的钆塞酸增强 MRI。
使用替代无反应接收器操作特性的 Jackknife 比较了特征曲线下的面积(FOM),并使用 McNemar 和 Fisher 检验比较了每个图像集的每个病变和每位患者的诊断参数。P<0.05 被认为具有统计学意义。
共在 13 名患者中发现 43 个肝转移灶。读者平均 FOM 以检测肝转移灶,集 2(0.884)和集 3(0.886)明显高于集 1(0.609),而集 2 和集 3 之间则相当(P=0.96)。集 2 和集 3 的每位患者的平均灵敏度、阴性预测值和准确率均明显高于集 1,而集 2 和集 3 之间则无显著差异(不适用,P>0.99 和 P>0.99)。
与单独 CECT 相比,钆塞酸增强 MRI 联合 CECT 对 PDAC 患者肝转移的检测具有更高的诊断性能。缩短的 MRI 和标准 MRI 的附加价值相当。
3 技术功效:2 级。